Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

User Fee Reauthorization: 'Pre-Conferenced' Bill Aims For Quick Passage

Executive Summary

'Clean' bill includes expanded access language from Senate, generic review revisions from House as legislators hope for enactment this month.

Advertisement

Related Content

Expanded Access: FDA To Clarify How Adverse Events Impact Drug Approval Process
Pediatric Cancer Study Requirements Added To FDA User Fee Bill
FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit
FDA User Fee Bill: House Cmte. Makes Technical Changes, Adds Pricing Resolution
Breakthrough-Style Program For ANDAs Added To House User Fee Bill
Expanded Access Amendment Could Blunt 'Right To Try' Legislation In US

Topics

Advertisement
UsernamePublicRestriction

Register

PS121072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel